Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
about
Review of the Structural and Dynamic Mechanisms of PPARγ Partial AgonismPartial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone massThe PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations.A subset of osteoblasts expressing high endogenous levels of PPARgamma switches fate to adipocytes in the rat calvaria cell culture model.Ethyl acetate fraction of Huogu formula inhibits adipogenic differentiation of bone marrow stromal cells via the BMP and Wnt signaling pathways.Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Marrow fat and bone--new perspectives.Regulation of early adipose commitment by Zfp521.β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells.A role for hedgehog signaling in the differentiation of the insertion site of the patellar tendon in the mouse.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.Effects of obesity on bone metabolism.Resolving the Two "Bony" Faces of PPAR-gamma.PPAR Gamma Activity and Control of Bone Mass in Skeletal Unloading.Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells.Diabetes, TZDs, and Bone: A Review of the Clinical Evidence.Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivoThe syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged boneA peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4.Tributyltin engages multiple nuclear receptor pathways and suppresses osteogenesis in bone marrow multipotent stromal cellsPeroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.Safety of Anti-Diabetic Therapies on Bone.Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.Fat targets for skeletal healthIs PPARγ a prospective player in HIV-1-associated bone disease?Marrow fat and the bone microenvironment: developmental, functional, and pathological implications.PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells.Negative influence of a long-term high-fat diet on murine bone architecture.Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophagesDiscovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Diabetes and skeletal health.Adiponectin and osteocalcin: relation to insulin sensitivity.Impact of diabetes and its treatments on skeletal diseases.Adipocytes and the regulation of bone remodeling: a balancing act.Review of Signaling Pathways Governing MSC Osteogenic and Adipogenic Differentiation.The bone and fat connection in inflammatory bowel diseases.
P2860
Q26782232-8202F81F-329B-48FB-8F3D-4A87452384A2Q27334866-C31F609E-D0CD-4C06-A69B-407C220CE200Q33351534-B8B28592-F076-469C-B4B1-7E3A972CFDD6Q33644501-C94EA341-B074-4E72-90DC-BB4944DD1546Q33703299-843CE1B9-435B-4175-9101-06260FF0D1BDQ33772312-B9C1BDAE-DB0C-4B8A-9554-87C8A31859E1Q33821740-BFEB07B5-AAC9-4E36-8FC0-D380ADE2527FQ34161200-B9A9FB9A-8C7C-43F3-9B4A-D83DF454F386Q34326863-1CBF5067-8AEC-4011-8E5B-30C296DE5B8BQ34499279-30773E7F-600C-48E9-887D-67A6AE76A402Q34525599-0E8095E7-3F04-49B9-B3A4-8D38480DB673Q34769898-71B83CCE-3DDF-49C7-9A06-8AA497641E58Q34888374-50D229F0-0B84-4F14-A73D-D5F3DF7B2F03Q35121884-5F693582-EEB5-4C7B-A2E4-4D1A2A6A8200Q35191573-61C47932-3AA2-4294-AB14-3EAFE7246982Q35191578-57958492-FEAB-486A-B115-EA1D01A6DC3FQ35496098-38DD6AD6-5312-4AE6-A8ED-F4E8F1F9E381Q35528700-9C5EF6CA-9DC2-4608-AD5C-37449C265961Q35606042-AC51C388-1300-413E-AF9B-FE236512339EQ35748476-E963B003-9A50-4810-A607-75AB49587DF7Q35990705-FBAA65E7-E171-484A-9EDD-471382CB4746Q36157326-D8FBE463-738C-4F48-8130-82107DC93D8FQ36238466-F1B2B27B-C4E1-4268-ADD1-DC4AB6F3C7B0Q36533766-31864CAC-3199-4345-9C3C-34FD27B48C58Q36715753-2703E9F7-6EA1-4A19-A0D8-B7496A68A873Q36716222-1EA6E9D3-4EB9-4CF9-A3FE-826BB275517AQ36830195-DF820CB9-0508-4C11-BA2D-1BAB07C007C3Q36866334-87A7CEED-A6D0-47FA-AA38-3BB1544BE871Q37137545-4082C71E-34D6-4F88-BE6F-6B6964F699C4Q37172974-C3076861-B2C1-4D9E-A749-DE219C628FF8Q37349947-55C837FD-E9ED-49FC-9A93-6B2D84CDA3E6Q37631449-E000EA15-4720-4A85-A117-91B69ED4B52FQ37693244-429C150E-197B-4958-89DB-31B0415D5B43Q37724195-CA140126-2272-4859-9D50-D4562F751CAFQ37798059-B813AA0A-A20C-4D05-B861-73370AEE8E44Q38027558-07E49CB2-2F19-4A24-9229-019EC697298BQ38078839-02C67A05-AC4A-4D66-8117-FE000E731CF3Q38150258-F18013DC-577C-456A-B72F-BA27E4B3ADA0Q38177814-48E32526-7BC9-415E-9E73-6119694E3104Q38225220-323A0B6F-F0DE-4E4E-B500-458DD724870B
P2860
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@ast
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@en
type
label
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@ast
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@en
prefLabel
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@ast
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
@en
P2093
P2860
P1433
P1476
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat
@en
P2093
Beata Lecka-Czernik
Oxana P Lazarenko
Sylwia O Rzonca
P2860
P356
10.1016/J.BONE.2005.07.008
P50
P577
2005-08-30T00:00:00Z